US Federal Court Orders FDA to Reconsider Mifepristone Restrictions, Labels Certification Rules “Arbitrary and Capricious”

A United States federal court has directed the Food and Drug Administration (FDA) to reconsider restrictions governing the prescription and dispensing of the abortion drug mifepristone, ruling that the agency failed to adequately justify the requirements.

In a decision delivered on Thursday, July 23, 2026, US District Judge Robert S. Ballou of the Western District of Virginia found that the FDA acted unlawfully by retaining special certification requirements for doctors and pharmacies despite repeatedly concluding that mifepristone is safe and effective.

The ruling came in the case of Whole Woman’s Health Alliance and Others v. United States Food and Drug Administration and Others, a lawsuit filed by abortion providers challenging the FDA’s continued regulation of the medication.

Judge Ballou held that the agency’s decision was “arbitrary and capricious,” saying it failed to establish a clear connection between its scientific findings on the drug’s safety and the need for the special certification process.

According to the judge, the FDA has consistently maintained over the past 25 years that mifepristone is a safe and effective medication. He added that the agency did not explain why removing the certification requirements would create enough risk to warrant withdrawing the drug from the market.

While the court ruled against the FDA’s reasoning, it stopped short of immediately striking down the restrictions. Instead, Judge Ballou ordered the agency, now under President Donald Trump’s administration, to review its regulations and determine whether they should be revised or eliminated.

As a result, the existing certification and documentation requirements will remain in effect while the FDA carries out its review, unless the court issues further orders.

The judge also noted that federal law allows the court to require the FDA to reconsider its decision but does not currently authorize it to invalidate the regulations outright.

The court is expected to later consider separate constitutional claims brought by the healthcare providers, a decision that could lead to additional legal action against the FDA.

The disputed rules are part of the FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Under the policy, healthcare providers must obtain special certification before prescribing the medication, while pharmacies are also required to be certified before dispensing it.

Patients must also review and sign a Patient Agreement Form confirming they have received information and counseling about the drug. Mifepristone can only be dispensed by certified providers or certified pharmacies acting on prescriptions issued by approved prescribers.

The lawsuit was filed in May 2023 by the Center for Reproductive Rights on behalf of Whole Woman’s Health Alliance, All Families Healthcare, Blue Mountain Clinic, and Trust Women. The plaintiffs argued that the FDA’s rules create unnecessary administrative hurdles, discourage providers and pharmacies from offering the medication, and delay access to time-sensitive healthcare.

They asked the court to eliminate the certification requirements for prescribers and pharmacies, as well as the mandatory Patient Agreement Form.

The FDA first approved mifepristone in 2000 for use with misoprostol to terminate pregnancies of up to 10 weeks. Over the years, the agency has eased some restrictions by removing the in-person dispensing requirement and allowing certified retail and mail-order pharmacies to distribute the drug, while maintaining the certification and documentation rules.

Mifepristone is now the most commonly used abortion medication in the United States, accounting for more than 60 percent of abortions nationwide.

The drug has remained at the center of legal and political disputes since the US Supreme Court’s 2022 Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade, allowing states to enforce their own abortion laws. Since then, several Republican-led states and anti-abortion groups have pursued legal efforts to restrict access to the medication.

The Trump administration is also conducting a broader review of mifepristone’s safety and regulatory framework. The FDA had not publicly responded to Judge Ballou’s ruling at the time of publication.

The decision comes as another legal battle continues over whether the drug can be prescribed through telemedicine and delivered by mail. In May 2026, the US Supreme Court allowed the FDA’s mail-distribution policy to remain in effect while a separate challenge from Louisiana remains on hold pending the agency’s broader review.

Reacting to the ruling, the Center for Reproductive Rights described the decision as a victory for science, arguing that the FDA’s restrictions were driven by political opposition to abortion rather than evidence-based safety concerns.

The organization’s president, Nancy Northup, said the judgment was particularly significant as mifepristone continues to face growing legal and political challenges across the United States.

Despite the ruling, individual states retain the authority to enforce their own abortion laws. The court’s decision is limited to requiring the FDA to reconsider the federal certification and documentation requirements for mifepristone.

… US Federal Court Orders FDA to Reconsider Mifepristone Restrictions, Labels Certification Rules “Arbitrary and Capricious” … Naijaonpoint.